CN105054001A - Nutritional formulations containing octenyl succinate anahydride-modified tapioca starch - Google Patents
Nutritional formulations containing octenyl succinate anahydride-modified tapioca starch Download PDFInfo
- Publication number
- CN105054001A CN105054001A CN201510421039.5A CN201510421039A CN105054001A CN 105054001 A CN105054001 A CN 105054001A CN 201510421039 A CN201510421039 A CN 201510421039A CN 105054001 A CN105054001 A CN 105054001A
- Authority
- CN
- China
- Prior art keywords
- nutritional preparation
- tapioca starch
- nutritional
- osa
- modified tapioca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
- A23L29/219—Chemically modified starch; Reaction or complexation products of starch with other chemicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pediatric Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Grain Derivatives (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
The present invention relates to a nutritional formulation comprising a lipid source, a carbohydrate source, a protein equivalent source, and an emulsifying agent comprising OSA-modified tapioca starch which contains less than about 0.05% non-protein nitrogen.
Description
The divisional application of the application's to be application number be 200780000662.7 female cases.The applying date of this female case is on May 15th, 2007; Denomination of invention is " comprising the nutritional preparation of octenyl succinate anahydride-modified tapioca starch ".
Technical field
The present invention relates in general to nutritional preparation.
Background technology
Food hypersenstivity is the clinical syndrome that a kind of immunology that can occur after the picked-up of dietary product mediates.With food hypersenstivity disadvantageous reaction may normally at once Immunoglobulin-E mediation reaction, be also called food protein allergy.HOST.A etc. " DietaryProductsUsedinInfantsforTreatmentandPreventionofF oodAllergy ", Arch.Dis.Child81:80-84(1999).The symptom of food protein allergy comprises angioedema, nettle rash, eczema (exzema), asthma, rhinitis, conjunctivitis, vomiting and allergic reaction.
Milk allergy is the modal food protein allergy of young children, has the incidence of about 2% to 3% in all babies.Sampson，H.A.FoodAllergy.Part1：ImmunopathogensisandClinicalDisorders，JAllergyClinImmunol.103:717-728（1999）。The cow's milk protein used in overwhelming majority's formula is considered to foreign protein.When infants are exposed to non-human milk, they can produce the antibody to foreign protein.It is stable that research has been presented at milk and the important foodstuffs anaphylactogen found in soy formulas to the digestion reaching 60 minutes (compared with the people lactoprotein digesting 15 minutes under one's belt) under one's belt.Foreign protein is by stomach subsequently, intactly arrives enteron aisle, obtains contact and may cause sensitization in enteron aisle.Immune system then " attack " foreign protein of baby, causes anaphylactoid symptom.
Being the complete milk protein found in most conventional infant formulas to a kind of possible explanation that protein allergy in baby is popular, is the earliest and the prevailing food hypersenstivity source that baby contacts.In fact, on market the formula of about 80% based on cow's milk.
Recent years, infant formula and child nutrition product are designed to attempt to reduce the incidence of disease of protein allergies.Such example comprises and uses hydrolysis cow's milk.Typically, the protein in this depth hydrolysis formula, for the object reducing allergic reaction, intolerance and sensitization, to have decomposed with ferment treatment partly or great majority cause the protein of unfavorable symptom.
Although protolysate is more hypoallergenic, they are not without allergen.HalkenS etc., TheEffectofHypoallergenicFormulasinInfantsatRiskofAllerg icDisease, Eur.J.Clin.Nutr.49(S1): S77-S83(1995).And then the new protein structure produced by this enzyme in hydrolyzed formulas may cause allergic reaction actually.HudsonM.J.，ProductDevelopmentHorizons-AViewfromIndustry，Eur.J.Clin.Nutr.49（S1）:S64-S70（1995）。In fact, in the children of Milk allergy, have about 10% to be also responsive to protein hydrolysate formulas.GiampietroP.G. etc., HypoallergenicityofanExtensivelyHydrolyzedWheyFormula, Pediatr.AllergyImmunol.12:83-86(2001).
The substitute selected of another kind of cow's milk is soy protein-based product.But unfortunately, soybean protein also may cause allergy or intolerance reaction.In fact, the baby of about 8% to 14% pair of Milk allergy is also to the protein allergy in soy formulations.ZeigerR.F. etc., SoyAllergyinInfantsandChildrenwithIgE-MediatedCowMilkAll ergy, J.Pediatr.134:614-622(1999).Soy protein allergy occurs the baby with above-mentioned cow milk protein allergy or intolerance history or not resistance to danger is comparatively large, may be that the intestinal mucosa infringement caused due to cow's milk protein causes.This infringement can allow soybean protein absorb to be increased, and promotes further reaction and symptom.
Therefore, for those to hydrolysis or soy-based formulas have anaphylactoid immunoenzyme technics, be common solution based on amino acid whose nutritional preparation.Amino acid is the basic structure construction unit of protein.Become by breaks down proteins their basic chemical structure (complete predigestion) that the amino acid-based formula of filling a prescription as minimum allergenicity can be obtained.The obtainable amino acid-based formula of several business and nutritious supplementary pharmaceutical comprise Neocate, L-Emental
tM, and Vivonex Plus.
For the baby having multiple food proteins resistance to or not irritated or children, amino acid-based formula also should avoid any composition protein may introduced in formula.But keep evenly for making formula and do not occur to be separated and various traditional emulsifying agent of being added in formula, comprising for sensitized individuals may be the protein of level of allergenicity.It can be seen from the above, there are the needs to nutritional preparation, and this nutritional preparation should be provided effective emulsification and do not introduced in preparation by emulsifying agent by the protein of potential level of allergenicity.
Summary of the invention
In brief, an embodiment of the invention correspond to a kind of novel nourishing preparation, it comprises lipid source, carbohydrate source, protein equivalent source and comprises the emulsifying agent of octenyl succinic acid anhydride (octenylsuccinateanhydride) (OSA)-modified tapioca starch, and described modified tapioca starch comprises the nonprotein nitrogen being less than about 0.05%.
Another embodiment of the invention corresponds to a kind of restructuring (reconstituted) nutritional preparation, its comprise lipid source, carbohydrate source, protein equivalent source and about 5% the emulsifying agent comprising OSA-modified tapioca starch, described restructuring nutritional preparation comprises the nonprotein nitrogen being less than about 5ppm.
Detailed description of the invention
To describe in detail embodiments of the present invention now, details are as follows for one or more embodiment.Each embodiment is provided for explaining the present invention, but not limitation of the invention.In fact, for those skilled in the art clearly, in the scope not departing from spirit of the present invention, various revision and change can be made to the present invention.Such as, as the feature that certain embodiment part institute illustrates or records, to may be used on another embodiment to yield a still further embodiment.
Thus, the invention is intended to be encompassed in the revision all of the present invention within the scope of incidental claims and equivalents thereof and change.Other target of the present invention, characteristic sum aspect are recorded in specific descriptions hereafter, or can obviously draw from specific descriptions hereafter.This area ordinary skill technical staff is to be understood that this discussion is only the record as typical embodiment, and is not intended to limit wider scope of the present invention.
The term " baby " used in the application is less than the people of about 1 years old after representing birth.
Term " children " or " children " represent after birth between the people about between 1 years old to 10 years old.
Term as used herein " infant formula " (infantformula) represents the composition being met infant nutrition demand by the substitute as human milk.
Term " nutritional preparation " (nutritionalformulation) represents any composition meeting the nutritional need of experimenter or the meal supplement as experimenter.
Term " protein equivalent " can comprise any protein source, such as soybean, egg, whey, or casein, also can be that non-protein sources is as amino acid.
Term " not containing albumen " represents by the measurement of standard protein measuring method such as dodecyl (lauryl) sodium sulphate polyacrylamide gel electrophoresis (SDS-PAGE) or size exclusion chromatography, not containing measurable protein.
Term used herein " partial hydrolysis " expression is greater than about 0% degree of hydrolysis being less than about 50%.
Term " depth hydrolysis " represents that degree of hydrolysis is more than or equal to about 50%.
Term " allergy " refers to immune system to the hypersensitivity of allergen that specifically can cause unfavorable symptom.
Term used herein " intolerance ", the specific unfavorable result occurred after referring to something on the feed, but it does not relate to immune system.Such as, food intolerance may not produce the decomposition food of q.s because of digestive system and help digest required certain enzyme or chemical substance and occur.
In one embodiment, the present invention corresponds to a kind of novel nourishing preparation, its emulsifying agent comprising lipid source, carbohydrate source, protein equivalent source and comprise OSA-modified tapioca starch, described modified tapioca starch contains and is less than about 0.05% nonprotein nitrogen.
In one embodiment, nutritional preparation can be nonprotein.Nutritional preparation can be infant formula or child nutrition product.Infant formula of the present invention can be term infant formula, or preterm infant formula.In some embodiments, the nutritional preparation be used in the present invention be nutrition completely, and comprise free amino acid, lipid, carbohydrate, vitamin and the mineral matter of proper types and quantity.
In a particular implementation of the present invention, protein equivalent source is the free amino acid of 100%.In this embodiment, nutritional preparation is without allergen.The amount of nutritional preparation Free Amino Acids typically can from about 1 to about changing 5g/100kcal.In one embodiment, the free amino acid of 100% has and is less than 500 daltonian molecular weight.
In another embodiment, protein equivalent source can comprise soybean protein, lactalbumin, casein, or egg protein.Protein can be complete, partial hydrolysis, or depth hydrolysis.
Another component of nutritional preparation of the present invention is lipid source.The amount of lipid typically can from about 3 to about changing 7g/100kcal.Lipid source can be any known or use in this area, such as vegetable oil such as palm oil, low shepherd's purse sauerkraut seed oil, corn oil, soybean oil, palm olein (palmolein), coconut oil, medium chain triglyceride oil, high gas oil ratio sunflower oil, high oleic safflower oil etc.
And another component of nutritional preparation is carbohydrate source.The amount of carbohydrate typically can from about 8 to about changing 12g/100kcal.Carbohydrate source can be any known or use in this area, such as lactose, glucose, corn-syrup solids, maltodextrin, sucrose, rice syrup solids etc.
Nutritional preparation of the present invention can also comprise the emulsifying agent containing OSA-modified tapioca starch.In some embodiments, OSA-modified tapioca starch comprises the nonprotein nitrogen being less than about 0.10%.In other embodiment, OSA-modified tapioca starch comprises the nonprotein nitrogen being less than about 0.05%.In some embodiments of the present invention, OSA-modified tapioca starch can comprise the nonprotein nitrogen being less than about 0.045%.In specific embodiment, OSA-modified tapioca starch can comprise the nonprotein nitrogen being less than about 0.04%.In some embodiments, OSA-modified tapioca starch is not containing protein.
OSA-modified tapioca starch can be complete or dextrinize.In some embodiments, in the present invention, the level of OSA-modified tapioca starch can in the scope of about 2% to about 15%.In other embodiment, in the present invention, the level of OSA-modified tapioca starch can in the scope of about 3% to about 10%.In further embodiment of the present invention, OSA-modified tapioca starch can within the scope of about 5% to about 15%.In particular implementation of the present invention, the level of OSA-modified tapioca starch can be about 5%.
In some embodiments of the present invention, tapioca be from cassava (cassava) or monioc plant (
manihotutilissima) obtain.This shrub typically grows into the height of 2 to 3 meters, has woody stems, the block root expanded.Tapioca is prepared by these roots and obtains.Tapioca is divided into two kinds of main kinds: bitter (
manihotpalmata) and sweet (
manihotaipi).Tapioca of the present invention can be bitter or sweet.In certain embodiments, tapioca is bitter kind.
In one embodiment, OSA-modified tapioca starch is the NATIONAL78-0701 produced by NationalStarch & ChemicalCompany.When using SDS-PAGE method to measure, this starch does not comprise any measurable protein.Use LECO2000CNS analyzer (LECO company, St.Joseph, MI, USA) and combustion methodologies, NATIONAL78-0701OSA-modified tapioca starch is recorded the nonprotein nitrogen comprising and be less than about 0.05%.
The OSA-modified tapioca starch used in the present invention can comprise the amylose between about 10% to 20% and the amylopectin between about 80% to 90%.In specific embodiment, OSA-modified tapioca starch can comprise the amylose of about 13% and the amylopectin of about 87%.
The OSA-modified tapioca starch used in the present invention is characterised in that excellent emulsion stability and encapsulating performance.It forms solid film on oil/water interface, stops emulsion agglomeration again.Although not wish by this or any theory fetter, be sure of that the OSA-modified tapioca starch used in the present invention is stabilizing agent, its molecule is made up of hydrophilic and hydrophobic (lipophilic) part.The hydrophobic part of emulsifying agent comprises OSA and the hydrophilic segment of emulsifying agent comprises tapioca.
It is believed that the ability that OSA-modified tapioca starch stablizes oil/water emulsion is associated with following event: described starch is through gelatine or heat to guarantee that starch is scattered in aqueous phase well enough, thus has the stablizing effect on oil-water interface.It former can not use in the low viscosity food system of starch accurately can control thickening.It has excellent dispersibility and stability.In addition this starch also heat-resisting, acid and in high shear force.The use of this starch in nutritional preparation is also provided as cream (creaminess) for formula itself extraly.
Be in the embodiment of about 5% in the level of OSA-modified tapioca starch, about 4% of total calorie (representing with 100kcal) of starch contributes nutritional preparation.In some embodiments of the present invention, OSA-modified tapioca starch is emulsifying agent unique in nutritional preparation and stabilizing agent.
In some embodiments, nutritional preparation of the present invention is hypoallergenic.In other embodiments, nutritional preparation be Jewish canon allow (kosher).Still in further embodiment, the gene-modified product of nutritional preparation right and wrong.Nutritional preparation is sucrose free in one embodiment.Nutritional preparation can be lactose-free in addition.Nutritional preparation does not comprise any medium chain triglyceride oil in other embodiments.In some embodiments, in nutritional preparation, carragheen is not contained.In other the embodiment also had, nutritional preparation is not containing all colloids.
In certain embodiments of the present invention, the pH of nutritional preparation is between about between 3 and 8.In other embodiment, the pH of nutritional preparation is between about between 6 and 7.In specific embodiment, the pH of nutritional preparation is between about between 5 and 6.In other embodiment also had, the pH of nutritional preparation is between about between 4 and 5.In specific embodiment, the pH of nutritional preparation is about 4.8.In other embodiment, the pH of nutritional preparation is about 5.5.In other the embodiment also had, the pH of nutritional preparation is about 6.5.
In some embodiments, the nutritional preparation of restructuring can between about 3.0 and 4.0 centipoises (cps) in the viscosity of 72 ℉.In other embodiments, the nutritional preparation of restructuring can between about between 3.2 and 3.6cps in the viscosity of 72 ℉.In other other embodiment, the nutritional preparation of restructuring can be about 3.4cps in the viscosity of 72 ℉.
Nutritional preparation of the present invention can be liquid (i.e. use or concentrated) or powder.If nutritional preparation is liquid, the storage life of nutritional preparation is at least 18 months.If nutritional preparation is powder, the storage life of nutritional preparation is at least 24 months.
In certain embodiments of the present invention, the nutritional preparation of restructuring comprises the nonprotein nitrogen being less than about 10ppm.In other embodiment, the nutritional preparation of restructuring comprises the nonprotein nitrogen being less than about 7ppm.Still in other embodiments, the nutritional preparation of restructuring comprises the nonprotein nitrogen being less than about 5ppm.In a specific embodiment, the nutritional preparation of restructuring comprises the nonprotein nitrogen of about 3.4ppm.In another embodiment, the nutritional preparation of restructuring comprises the nonprotein nitrogen of about 2.97ppm.
Be appreciated that in recombination preparation, the total amount of nonprotein nitrogen depends on the amount of nonprotein nitrogen in OSA-modified tapioca starch and the OSA-tapioca starch present in nutritional preparation.Thus the combination producing these two factors of ppm total is as above in the present invention involved.
In one embodiment, the present invention can comprise a kind for the treatment of and has the not resistance to disease of food proteins or the baby of allergy or the method for children.The method comprises with nutritional preparation feeding infant of the present invention or children.In some embodiments, baby or children have the demand to this treatment.Term " demand " can mean that these babies or children are in the risk of the not resistance to disease of generation or allergy.If there are high family's allergies, baby or children may be in this risk, or due to meals, disease, wound, or physical disturbances and being in this risk.In some embodiments, to there is the not resistance to disease of multiple food proteins or hypersensitive Infants'feeding nutritional preparation of the present invention can prevent potential anaphylactoid generation.
DHA and ARA has the previously shown health to immunoenzyme technics and contributive long-chain polyunsaturated fatty acid (LCPUFA) of growing up.Giving in breast-fed babies, typically DHA and ARA is obtained by breast milk.But for the baby of formula feeding, DHA and ARA must be added in meals.In some embodiments of the present invention, nutritional preparation comprises DHA.In some embodiments of the present invention, nutritional preparation comprises DHA and ARA.
In an embodiment of the invention, the part by weight scope of ARA:DHA is from about 10:1 to about 1:10.In another embodiment of the present invention, this proportion is from about 5:1 to about 1:5.In the other embodiment also had, this proportion is that about 3:1 is to about 1:3.In a specific embodiment, this proportion is that about 3:1 is to about 1:2.In another particular implementation of the present invention, this ratio is about 2:1.
In certain embodiments of the present invention, the level of DHA is between account for aliphatic acid about 0.20% to 0.50%.In other embodiments of the present invention, the level of DHA is account for aliphatic acid about 0.35%.In the other embodiment also had of the present invention, the level of ARA is between account for aliphatic acid 0.60% to 0.80%.In a specific embodiment, the level of ARA is account for aliphatic acid 0.72%.In some embodiments of the present invention, only in preparation, DHA is supplemented.
In an embodiment of the invention, the amount of DHA can be from about 3mg every kg body weight every day to about 150mg per kilogram of body weight every day.In an embodiment of the invention, this amount is for from about 6mg per kilogram of body weight every day to about 100mg per kilogram of body weight every day.This amount is for from about 15mg per kilogram of body weight every day to about 60mg per kilogram of body weight every day in another embodiment.
In one embodiment of the present invention, the amount of ARA can from about 5mg every kg body weight every day to about 150mg per kilogram of body weight every day.In an embodiment of the invention, this amount from about 10mg per kilogram of body weight every day to about 120mg per kilogram of body weight every day change.In another embodiment, this amount changes for from about 15mg per kilogram of body weight every day to about 90mg per kilogram of body weight every day.In another embodiment also had, this amount from about 20mg per kilogram of body weight every day to about 60mg per kilogram of body weight every day change.
Amount for DHA in the nutritional preparation of one embodiment of the present invention can at about 2mg/100 kilocalorie (kcal) to about changing between 100mg/100kcal.In another embodiment, the amount of DHA at about 5mg/100kcal to about changing between 75mg/100kcal.In another embodiment also had, the amount of DHA at about 15mg/100kcal to about changing between 60mg/100kcal.
Amount for ARA in the nutritional preparation of one embodiment of the present invention can from about 4mg/100 kilocalorie (kcal) to about 100mg/100kcal.In another embodiment, the amount of ARA at about 10mg/100kcal to about changing between 67mg/100kcal.In another embodiment also had, the amount of ARA at about 20mg/100kcal to about changing between 50mg/100kcal.In a particular implementation, the amount of ARA at about 30mg/100kcal to about changing between 40mg/100kcal.
For employing of the present invention comprise DHA and ARA oils supplement nutritional preparation can use standard technique well known in the art to manufacture.The oil such as high gas oil ratio sunflower oil of the conventional equivalent existed in nutritional preparation such as can be replaced with DHA and ARA.
The source of ARA and DHA can be any source known in the art, such as fish oil, single cell oil (singlecelloil), yolk fat, brain fat etc.DHA and ARA can be native form, and condition is any essence can not be caused in the LCPUFA source retained illeffects to baby.Selectively, DHA and ARA can use with refined form.
The source of DHA and ARA can be as U.S. Patent No. 5,374,657,5,550,156, and 5,397,591 single cell oils of instructing, the content disclosed in them is incorporated herein by reference in full at this.
In certain embodiments of the present invention, DHA is derived from single cell oil.In another embodiment of the present invention, ARA is derived from single cell oil.In certain embodiments, DHA and ARA is derived from single cell oil.
LCPUFA source can comprise or can not comprise eicosapentaenoic acid (EPA).In some embodiments, the LCPUFA used in the present invention comprises a small amount of or not containing EPA.Such as, in some embodiments, nutritional preparation comprises the EPA being less than about 20mg/100kcal; In some embodiments, the EPA of about 10mg/100kcal is less than; In other embodiments, be less than the EPA of about 5mg/100kcal; Substantially not containing EPA in the other embodiment also had.
In some embodiments, the OSA-modified tapioca starch that non-protein nitrogen content is less than about 0.05% can add standard infant formula, hydrolyzed protein infant formula, lactose free infant formula, soy protein infant formula, hydrolyzed soy protein infant formula, any nutritional preparation needing additional viscosity to, or in the nutritional preparation of the stronger emulsion of any needs.Such as, the OSA-modified tapioca starch with the non-protein nitrogen content being less than about 0.05% can be joined Enfamil, Enfamil preterm formula, iron content Enfamil, Lactofree, Nutramigen, Pregestimil, Lipil or ProSobee (can from MeadJohnson & Company, Evansville, IN, USA obtain) in.Also the OSA-modified tapioca starch with the non-protein nitrogen content being less than about 0.05% can be joined in various baby, children and adult nutritional products.
Implementation described below illustrates various embodiment of the present invention.Consider and of the present inventionly as disclosed herein illustrate and put into practice, other embodiment in right is also apparent to those skilled in the art.Will be understood that, description and embodiment are only exemplary, and the claim after embodiment is used for showing scope and spirit of the present invention.In these embodiments, except as otherwise noted, all percentage all provides based on weight.
embodiment 1
This example illustrates an embodiment of nutritional preparation of the present invention.Table 1 lists the component of the embodiment of powdered nutritional supplement of the present invention, and they are with gram (g) of every 100kg nutritious supplementary pharmaceutical or kilogram amount that (kg) represents.
Table 1: component information and content (every 100kg)
| Component, unit | Every 100kg |
| Powder of amino acids matrix, kg | 64.992 |
| Corn-syrup solids, kg | 29.169 |
| The fat blend of bulk, kg | 25.926 |
| Palm olein, kg | 11.667 |
| Soybean oil, kg | 5.185 |
| Coconut oil, kg | 5.185 |
| High gas oil ratio sunflower oil, kg | 3.889 |
| Calcium monohydrogen phosphate, kg | 1.600 |
| Potassium citrate, kg | 0.333 |
| Unicellular ARA and DHA, kg | 0.724 |
| OSA-modified tapioca starch, kg | 5.000 |
| Calcium citrate, kg | 0.330 |
| Two citric acid monohydrate sodium particles, kg | 0.273 |
| Potassium chloride, kg | 0.189 |
| Choline Chloride, kg | 0.196 |
| Spongiosa magnesia, kg | 0.091 |
| Calcium hydroxide, kg | 0.147 |
| L-BETAIN, g | 14.398 |
| Sodium iodide, g | 0.095 |
| Corn-syrup solids, kg | 14.540 |
| Essential amino acid pre-composition, kg | 9.8 |
| L-Leu, kg | 1.736 |
| Lysine hydrochloride, kg | 1.408 |
| Valine, kg | 1.068 |
| ILE, kg | 0.956 |
| Corn-syrup solids, kg | 0.890 |
| L-threonine, kg | 0.864 |
| TYR, kg | 0.765 |
| L-Phe, kg | 0.708 |
| L-Histidine, kg | 0.371 |
| CYSTINE, kg | 0.371 |
| L-Trp, kg | 0.337 |
| METHIONINE, kg | 0.326 |
| Nonessential amino acid pre-composition, kg | 9.8 |
| L-Aspartic acid, kg | 2.822 |
| L-PROLINE, kg | 1.406 |
| ALANINE, kg | 1.375 |
| Corn-syrup solids, kg | 1.249 |
| Monosodium glutamate, kg | 0.967 |
| Serine, kg | 0.865 |
| L-arginine, kg | 0.745 |
| Glycine, kg | 0.371 |
| Dry vitamin premix, kg | 0.403 |
| Ascorbic acid, g | 149.352 |
| Inositol, g | 99.541 |
| Corn-syrup solids, low sodium, DE 24, g | 62.377 |
| Taurine, g | 35.343 |
| Dry D-α-tocopherol acetate, g | 25.792 |
| Vitamin A microencapsulation (beadlet), g | 7.967 |
| Niacinamide, g | 6.416 |
| The dry vitamin K1 of 1%, g | 5.078 |
| Calcium pantothenate, g | 3.982 |
| Vitamin B12 in the starch of 0.1%, g | 2.337 |
| The biotin development powder of 1%, g | 2.176 |
| Vitamine D3 powder, g | 0.850 |
| Thiamine hydrochloride, g | 0.633 |
| Riboflavin, g | 0.580 |
| Puridoxine hydrochloride, g | 0.455 |
| Folic acid, g | 0.121 |
| For the trace/ultra-trace mineral pre-composition of amino acid formula, kg | 0.235 |
| Corn-syrup solids, g | 218.818 |
| Single zinc sulphate hydrate, g | 14.126 |
| Sodium selenite, g | 7.050 |
| Copper sulphate, powder, g(CuSO 45H 2O） | 0.035 |
| Single hydrated manganese sulfate, g | 1.692 |
| Iron grounds travel, kg | 0.230 |
| Corn-syrup solids, g | 178.238 |
| Ferrous sulfate, g | 46.00 |
| Ascorbic acid, g | 5.762 |
Table 2 lists the content of related component in the nutritional preparation of embodiment 1.
Table 2: constituent content
| Component, unit | Every 100g powder | Every 100mL |
| Protein equivalent, g | 14.34 | 1.95 |
| Lipid, g | 26.67 | 3.63 |
| Carbohydrate, g | 53.82 | 7.32 |
| Ash content, g | 2.78 | 0.38 |
| Moisture, g | 2.39 | |
| Calorie, kcal | 510 | 69.3 |
The calorie distribution of the nutritional preparation in embodiment 1 describes in table 3.
Table 3: calorie distributes
| Component | Calorie percentage |
| Protein equivalent | 11.12% |
| Lipid | 47.36% |
| Carbohydrate | 41.52% |
Embodiment 2
This example illustrates another embodiment of nutritional preparation of the present invention.Table 4 lists the nutrition composition in the embodiment of given nutritious supplementary pharmaceutical and they are with every 100 calories of amounts represented.
Table 4 nutritional labeling
| (normal dilution) | Every 100 calories (5 fluid ounce) |
| Protein, g | 2.8 |
| Fat, g | 5.3 |
| Linoleic acid, mg | 1040 |
| DHA，mg | 17 |
| ARA，mg | 34 |
| Carbohydrate, g | 10.3 |
| Water, g | 133 |
| Vitamin A, IU | 300 |
| Vitamin D, IU | 50 |
| Vitamin E, IU | 2 |
| Vitamin K, μ g | 8 |
| Thiamines (vitamin B1), μ g | 80 |
| Riboflavin (vitamin B2), μ g | 90 |
| Vitamin B6, μ g | 60 |
| Vitamin B12, μ g | 0.3 |
| Nicotinic acid, μ g | 1000 |
| Folic acid, μ g | 16 |
| Pantothenic acid, μ g | 500 |
| Biotin, μ g | 3 |
| Vitamin C (ascorbic acid), mg | 12 |
| Choline, mg | 24 |
| Inositol, mg | 17 |
| Carnitine, mg | 2 |
| Taurine, mg | 6 |
| Calcium, mg | 94 |
| Phosphorus, mg | 52 |
| Magnesium, mg | 11 |
| Iron, mg | 1.8 |
| Zinc, mg | 1 |
| Manganese, μ g | 25 |
| Copper, μ g | 75 |
| Iodine, μ g | 15 |
| Selenium, μ g | 2.8 |
| Sodium, mg | 47 |
| Potassium, mg | 110 |
| Chlorine, mg | 86 |
Table 5 lists the nutritional labeling concentration (nutrientdensity) with related component in embodiment 2 nutritional preparation, every 20 calories/fluid ounce.
Table 5: nutritional labeling concentration
embodiment 3
This example illustrates another embodiment of nutritional preparation of the present invention.Table 6 lists the nutrition composition in given liquid nutritional supplement embodiment and they are with every 100 calories of amounts represented.
Table 6: nutritional labeling
Table 7 lists the nutritional labeling concentration of the related component of embodiment 3 Middle nutrition preparation.
Table 7: nutritional labeling forms (nutrientfacts)
embodiment 4
This example illustrates a kind of method manufacturing nutritional preparation of the present invention.At 55 DEG C, fat blend and lipid oils are mixed together.Then this fat blend and water are mixed at 60 DEG C, obtain substrate mixture.Afterwards, at 60 DEG C, various mineral matter such as potassium citrate, natrium citricum, potassium chloride, Choline Chloride, calcium hydroxide, carnitine, sodium iodide are mixed with water, and join in substrate mixture.Then, calcium monohydrogen phosphate, calcium citrate and magnesia are joined in substrate mixture.Tapioca and corn-syrup solids are joined in substrate mixture.
Subsequently to substrate mixture direct steam injection about 25 seconds.Then be cooled to 65 DEG C by instantaneous for mixture, and homogenize and preserve.Then by the metre filter mixture of a 1mm.Subsequently by filtered heating materials to 80 DEG C, and spraying dry is to produce powder.Powder has the moisture of about 2% to 3%.Subsequently powder is cooled, cross the sieve of 2mm, and be packaged into the sack of 20kg.
The change of these manufacturing process any is all known or apparent to those skilled in the art.Unintentionally the present invention is limited to any specific manufacturing process.
embodiment 5
This example illustrates the mensuration of the storage life of nutritional preparation of the present invention.For obtaining information, use the condition (higher temperature and humidity) accelerated to measure the impact of unfavorable condition of storage on product.Prepare and pack the sample of the nutritional preparation of embodiment 1.Sample storage in 37 ± 3 DEG C and 85% relative humidity (RH) under two weeks, under being stored in room temperature during remaining research subsequently (22 ± 2 DEG C, relative humidity 50%).Period is imitated transport and handling condition in this storage.Then sample storage carries out the investigation of quality assurance for 24 months.
All stability result are all acceptable.Powdered nutritional formulation records the storage life with at least 24 months, and liquid nutritional formulation of recombinating records the storage life with at least 18 months.The trophic level that stability result is judged as satisfied physics, chemistry and organoleptic properties and has in given area.The most I accepted thing reason of samples met is evaluated, and comprises in product and there is minimum or gel-free, precipitation, fat serum, and grain.Do not observe liquid flocculation or fat aggregation in the product.Within the storage life, color and organoleptic feature change very little or not change.Light and heat sensitivity vitamin is in mark promise state or higher than its state within the storage life.Thus stability result is acceptable in the specific time limit.
All bibliography quoted from this manual, comprise and be not limited to all papers, publication, patent, patent application, image, textbook, report, manuscript, pamphlet, books, internet mail, articles published in newspapers or periodicals, periodical etc., hereby to introduce in full in this description as a reference, but degree of quoting is to the conflict do not formed any content comprised herein.
Only be intended to summarize the judgement done by its author to the discussion of bibliography herein, do not admit that any bibliography constitutes prior art.The applicant retains the correctness of challenge institute incorporated by reference document and the right of correlation.
Although used particular term, equipment and method preferred embodiment to describe of the present invention, these have described only for illustrative purposes.The word used is narrative and nonrestrictive.Should be appreciated that this area ordinary skill technical staff can, under the spirit or scope of the present invention not departing from the claim as hereafter provided, carry out changing and adjusting.In addition, should be appreciated that the exchange of entirety or part can be carried out in the aspect of various embodiment.
Claims (12)
1. a nutritional preparation, comprise lipid source, carbohydrate source, protein equivalent source and emulsifying agent, described emulsifying agent is OSA-modified tapioca starch, and described OSA-modified tapioca starch contains the nonprotein nitrogen being less than about 0.05%, and wherein protein equivalent source is amino acid.
2. nutritional preparation according to claim 1, wherein OSA-modified tapioca starch comprises the nonprotein nitrogen being less than about 0.045%.
3. nutritional preparation according to claim 1, wherein OSA-modified tapioca starch comprises the nonprotein nitrogen being less than about 0.040%.
4. nutritional preparation according to claim 1, wherein OSA-modified tapioca starch is not containing protein.
5. nutritional preparation according to claim 1, wherein OSA-modified tapioca starch is complete.
6. nutritional preparation according to claim 1, wherein nutritional preparation is hypoallergenic.
7. nutritional preparation according to claim 1, wherein in nutritional preparation, the level of OSA-modified tapioca starch accounts for about 2% to 15% of formula.
8. nutritional preparation according to claim 1, wherein in nutritional preparation, the level of OSA-modified tapioca starch accounts for 2% to 5% of formula.
9. nutritional preparation according to claim 1, wherein the form of nutritional preparation is selected from liquid and powder.
10. nutritional preparation according to claim 1, comprises DHA source in addition.
11. nutritional preparations according to claim 1, comprise DHA source and ARA source in addition.
12. nutritional preparations according to claim 1, wherein nutritional preparation is infant formula.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/494970 | 2006-07-28 | ||
| US11/494,970 US20080026105A1 (en) | 2006-07-28 | 2006-07-28 | Nutritional formulations containing octenyl succinate anhydride-modified tapioca starch |
| CNA2007800006627A CN101330835A (en) | 2006-07-28 | 2007-05-15 | Nutritional formulations comprising octenyl succinic anhydride-modified tapioca starch |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800006627A Division CN101330835A (en) | 2006-07-28 | 2007-05-15 | Nutritional formulations comprising octenyl succinic anhydride-modified tapioca starch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105054001A true CN105054001A (en) | 2015-11-18 |
Family
ID=38702019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800006627A Pending CN101330835A (en) | 2006-07-28 | 2007-05-15 | Nutritional formulations comprising octenyl succinic anhydride-modified tapioca starch |
| CN201510421039.5A Pending CN105054001A (en) | 2006-07-28 | 2007-05-15 | Nutritional formulations containing octenyl succinate anahydride-modified tapioca starch |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007800006627A Pending CN101330835A (en) | 2006-07-28 | 2007-05-15 | Nutritional formulations comprising octenyl succinic anhydride-modified tapioca starch |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20080026105A1 (en) |
| EP (1) | EP1898719A2 (en) |
| KR (1) | KR20090045824A (en) |
| CN (2) | CN101330835A (en) |
| BR (1) | BRPI0702887A2 (en) |
| CA (1) | CA2613172C (en) |
| HK (1) | HK1217415A1 (en) |
| MY (1) | MY166539A (en) |
| NO (1) | NO20076300L (en) |
| RU (1) | RU2007148333A (en) |
| TW (2) | TWI482594B (en) |
| WO (1) | WO2008014041A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114888915A (en) * | 2022-05-13 | 2022-08-12 | 安徽德润工艺品有限公司 | Processing method for tough-woven wicker |
| CN117813016A (en) * | 2021-07-28 | 2024-04-02 | N·V·努特里奇亚 | Method for preparing powders by spray drying and powders obtainable therefrom |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075017A1 (en) * | 2007-03-30 | 2010-03-25 | Toshihide Nishimura | Salty taste enhancer, food or drink and method for producing food or drink |
| US20100004334A1 (en) * | 2008-07-01 | 2010-01-07 | Mead Johnson Nutrition Company | Nutritional Compositions Containing Punicalagins |
| US20110311704A1 (en) * | 2009-02-10 | 2011-12-22 | Cargill Incorporated | Emulsion-like compositions |
| US20110019354A1 (en) * | 2009-03-02 | 2011-01-27 | Christopher Prest | Techniques for Strengthening Glass Covers for Portable Electronic Devices |
| WO2010143053A1 (en) * | 2009-06-10 | 2010-12-16 | Energy4Life Ag | Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders |
| DE102011087715A1 (en) | 2011-12-05 | 2013-07-25 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | HARDWARE-COATED METAL, HARD-METAL, CERMET OR CERAMIC BODIES AND METHOD FOR THE PRODUCTION OF SUCH BODIES |
| SG11201403644SA (en) * | 2011-12-30 | 2014-07-30 | Abbott Lab | Stabilized concentrated liquid human milk fortifier |
| EP2797435A2 (en) * | 2011-12-30 | 2014-11-05 | Abbott Laboratories | Concentrated low water activity liquid human milk fortifier including extensively hydrolyzed protein |
| US20140242216A1 (en) * | 2013-02-24 | 2014-08-28 | Mead Johnson Nutrition Company | Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System |
| US20150119505A1 (en) * | 2013-10-29 | 2015-04-30 | Edward Scott Williams | Paper Coating Composition |
| US20160353775A1 (en) * | 2015-06-04 | 2016-12-08 | Balchem Corporation | Hydration Control for Choline Salts |
| US10124036B2 (en) * | 2015-06-12 | 2018-11-13 | Cambrooke Therapeutics, Inc. | Liquid nutritional formula for tyrosinemia patients |
| BR102016009579A2 (en) * | 2016-04-28 | 2017-10-31 | Geralatex Indl E Coml Prod Agro Florestais | NUTRITIONAL FOOD SUPPLEMENT FORMULATED ON THE BASIS OF PULP OR HUMID WATERMELON FACTOR, MODIFIED BY HYDRATION OR REIDRATING, ALSO KNOWN AS TAPIOCA ATHLETES OR PRACTICERS OF PHYSICAL ACTIVITIES, ITS COMPOSITIONS AND PROCESS |
| CN112841507B (en) * | 2021-03-15 | 2022-12-02 | 新疆大唐西域农业生态科技有限公司 | Freeze-dried rice noodles and preparation method thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035235A (en) * | 1973-03-12 | 1977-07-12 | Anheuser-Busch, Incorporated | Method of making lipophilic starch derivatives |
| US4414238A (en) * | 1981-12-24 | 1983-11-08 | Cutter Laboratories, Inc. | Liquid elemental diet |
| ZA86415B (en) * | 1985-01-29 | 1986-09-24 | Abbott Lab | Enteral nutritional hypoallergenic formula |
| US4670268A (en) * | 1985-01-29 | 1987-06-02 | Abbott Laboratories | Enteral nutritional hypoallergenic formula |
| US5185176A (en) * | 1988-03-11 | 1993-02-09 | National Starch And Chemical Investment Holding Corporation | Food products containing modified starch emulsifier |
| US5407957A (en) * | 1990-02-13 | 1995-04-18 | Martek Corporation | Production of docosahexaenoic acid by dinoflagellates |
| RU2093996C1 (en) * | 1991-01-24 | 1997-10-27 | Мартек Корпорейшн | Method of addition to child's nutrient mixture of docosahexanoic and arachidonic acids (versions) and composition (versions) |
| US5514655A (en) * | 1993-05-28 | 1996-05-07 | Abbott Laboratories | Enteral nutritional with protein system containing soy protein hydrolysate and intact protein |
| US5480865A (en) * | 1994-02-25 | 1996-01-02 | Parkinson's Charitable Trust | Nutritional composition |
| US6007856A (en) * | 1997-08-08 | 1999-12-28 | The Procter & Gamble Company | Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid |
| US6051270A (en) * | 1997-11-05 | 2000-04-18 | Galagen, Inc. | Liquid amino acid nutritional composition |
| US6288116B1 (en) * | 1998-05-13 | 2001-09-11 | Novartis Nutrition Ag | Method of administration of a nutritional product to a person having renal failure |
| US6077558A (en) * | 1998-12-23 | 2000-06-20 | Bristol-Myers Squibb Company | Elemental nutritional products |
| US6365218B1 (en) * | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
| US20040143013A1 (en) * | 2000-02-28 | 2004-07-22 | Bristol-Myers Squibb Company | Use of docosahexaenoic acid and arachidonic acid enhancing the growth of preterm infants |
| US20030165606A1 (en) * | 2001-07-18 | 2003-09-04 | Lasekan John B. | Anti-regurgitation formula and uses thereof |
| US20050175759A1 (en) * | 2004-02-09 | 2005-08-11 | Atul Singhal | Newborn infant formulas and feeding methods |
| US6809197B1 (en) * | 2003-06-11 | 2004-10-26 | Mgp Ingredients, Inc. | Emulsion stabilizing starch products |
-
2006
- 2006-07-28 US US11/494,970 patent/US20080026105A1/en not_active Abandoned
-
2007
- 2007-05-15 KR KR1020077030644A patent/KR20090045824A/en not_active Ceased
- 2007-05-15 RU RU2007148333/13A patent/RU2007148333A/en not_active Application Discontinuation
- 2007-05-15 CN CNA2007800006627A patent/CN101330835A/en active Pending
- 2007-05-15 MY MYPI20072156A patent/MY166539A/en unknown
- 2007-05-15 BR BRPI0702887-3A patent/BRPI0702887A2/en not_active IP Right Cessation
- 2007-05-15 WO PCT/US2007/068925 patent/WO2008014041A2/en not_active Ceased
- 2007-05-15 EP EP07797470A patent/EP1898719A2/en not_active Ceased
- 2007-05-15 CN CN201510421039.5A patent/CN105054001A/en active Pending
- 2007-05-15 CA CA2613172A patent/CA2613172C/en active Active
- 2007-07-04 TW TW096124363A patent/TWI482594B/en not_active IP Right Cessation
- 2007-07-04 TW TW103146544A patent/TWI606787B/en not_active IP Right Cessation
- 2007-12-07 NO NO20076300A patent/NO20076300L/en not_active Application Discontinuation
-
2011
- 2011-09-09 US US13/229,256 patent/US20120064220A1/en not_active Abandoned
-
2016
- 2016-05-12 HK HK16105416.7A patent/HK1217415A1/en unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117813016A (en) * | 2021-07-28 | 2024-04-02 | N·V·努特里奇亚 | Method for preparing powders by spray drying and powders obtainable therefrom |
| US12446606B2 (en) | 2021-07-28 | 2025-10-21 | N.V. Nutricia | Process for preparing powders by spray drying and powders obtainable thereby |
| CN114888915A (en) * | 2022-05-13 | 2022-08-12 | 安徽德润工艺品有限公司 | Processing method for tough-woven wicker |
| CN114888915B (en) * | 2022-05-13 | 2023-02-17 | 安徽德润工艺品有限公司 | Processing method for tough-woven wicker |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2613172C (en) | 2016-07-05 |
| TW201528969A (en) | 2015-08-01 |
| TW200816933A (en) | 2008-04-16 |
| BRPI0702887A2 (en) | 2009-01-20 |
| HK1217415A1 (en) | 2017-01-13 |
| CA2613172A1 (en) | 2008-01-28 |
| WO2008014041A2 (en) | 2008-01-31 |
| RU2007148333A (en) | 2009-07-10 |
| US20080026105A1 (en) | 2008-01-31 |
| MY166539A (en) | 2018-07-10 |
| TWI606787B (en) | 2017-12-01 |
| NO20076300L (en) | 2008-02-26 |
| WO2008014041A3 (en) | 2008-03-13 |
| TWI482594B (en) | 2015-05-01 |
| KR20090045824A (en) | 2009-05-08 |
| CN101330835A (en) | 2008-12-24 |
| EP1898719A2 (en) | 2008-03-19 |
| US20120064220A1 (en) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105054001A (en) | Nutritional formulations containing octenyl succinate anahydride-modified tapioca starch | |
| TW410160B (en) | Adolescent dietary composition | |
| JP6857175B2 (en) | Liquid nutritional composition containing micelle casein and hydrolyzed whey protein | |
| US5922766A (en) | Palatable elemental medical food | |
| TWI250848B (en) | Infant formula with improves protein content | |
| TWI241167B (en) | Improved pediatric formula and methods for providing nutrition and improving tolerance | |
| EP1148791B1 (en) | Protein material for slow digestion and its use | |
| TW301600B (en) | ||
| CN101163409A (en) | Low-lactose partially hydrolyzed infant formula | |
| WO2002015719A2 (en) | Nutritional composition | |
| IE58454B1 (en) | Enteral nutritional hypoallergenic formula | |
| EP2797431A1 (en) | Reduced calorie infant formulas containing specific whey to casein ratios | |
| WO2005018343A1 (en) | Calcium fortified soy based infant nutritional formulas | |
| CN103402375A (en) | Low calorie infant formula with improved physical attributes | |
| HK1133554A (en) | Nutritional formulations containing octenyl succinate anahydride-modified tapioca starch | |
| TW201233328A (en) | Reduced buffering capacity of a low calorie infant formula | |
| MX2007015467A (en) | Nutritional formulations containing octenyl succinate anahydride-modified tapioca starch | |
| TW201306753A (en) | Improved rate of protein digestion in a low calorie infant formula | |
| MXPA99011693A (en) | Palatable elemental medical food | |
| MXPA06001894A (en) | Calcium fortified soy based infant nutritional formulas | |
| HK1028713B (en) | Palatable elemental medical food | |
| TW201233330A (en) | Nutritional products including a novel fat system including fatty acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1217415 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151118 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1217415 Country of ref document: HK |